Raymond James & Associates Reduces Stock Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Raymond James & Associates lessened its holdings in OraSure Technologies, Inc. (NASDAQ:OSURFree Report) by 52.5% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,391 shares of the medical instruments supplier’s stock after selling 13,713 shares during the period. Raymond James & Associates’ holdings in OraSure Technologies were worth $62,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC raised its position in shares of OraSure Technologies by 249.6% in the second quarter. FMR LLC now owns 10,687 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 7,630 shares in the last quarter. 1832 Asset Management L.P. purchased a new stake in shares of OraSure Technologies in the first quarter worth $40,000. UBS Group AG raised its position in shares of OraSure Technologies by 82.3% in the third quarter. UBS Group AG now owns 11,217 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 5,064 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of OraSure Technologies in the third quarter worth $49,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in shares of OraSure Technologies in the third quarter worth $58,000. Hedge funds and other institutional investors own 88.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on OSUR. JPMorgan Chase & Co. lowered their price objective on OraSure Technologies from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 8th. TheStreet upgraded OraSure Technologies from a “d+” rating to a “c” rating in a research report on Wednesday, November 8th. Finally, StockNews.com downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th.

View Our Latest Analysis on OraSure Technologies

OraSure Technologies Trading Up 4.0 %

Shares of NASDAQ:OSUR opened at $6.80 on Wednesday. The stock’s 50-day moving average price is $5.69 and its 200-day moving average price is $5.63. OraSure Technologies, Inc. has a 12-month low of $4.38 and a 12-month high of $7.82. The stock has a market capitalization of $499.69 million, a P/E ratio of 10.06 and a beta of 0.03.

OraSure Technologies (NASDAQ:OSURGet Free Report) last announced its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.20. OraSure Technologies had a return on equity of 14.88% and a net margin of 10.86%. The firm had revenue of $89.18 million for the quarter, compared to analysts’ expectations of $74.56 million. During the same period last year, the firm earned $0.07 earnings per share. The company’s revenue for the quarter was down 23.4% compared to the same quarter last year. As a group, research analysts predict that OraSure Technologies, Inc. will post 0.62 EPS for the current year.

OraSure Technologies Profile

(Free Report)

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions.

Further Reading

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.